Reimbursement is one of the cornerstone aspects of successful market penetration for a follow-on product. Drug and biologic sponsors must be fully aware of who the major payors are, their priorities and criteria. While the biosimilar product class is still new in North America, there is a tremendous amount that they can learn from the successful establishment of reimbursement guarantees enjoyed by small-molecule generics. What business relationships must you set up with healthplans, pharmacies, PBMs, employers, and other major players in this space to guarantee good ROI?
At the
Business of Biosimilars and Generic Drugs taking place September 10-12, 2012 in Boston, MA, Steven Goldberg, Chief of Medical Affairs, Express Scripts and Michael Castagna, Executive Director of Immunoscience, Bristol-Myers Squibb will be presenting "Reimbursement Strategies for Generics & Biosimilars Around the World," examining this topic. For more on this year's event,
download the brochure. If you'd like to join us in Boston, register and mention code XP1786BLOG to save 25% off the standard rate.
 |
Speaker Michael Castagna,
BRISTOL-MYERS SQUIBB |
Featured Session: Reimbursement Strategies for Generics & Biosimilars Around the World
Featured Speakers: Steven Goldberg, Chief of Medical Affairs, EXPRESS SCRIPTS
Michael Castagna, Executive Director of Immunoscience, BRISTOL-MYERS SQUIBB
About the session:
Global rollouts of new biopharma products require an in-depth understanding of the reimbursement mechanisms in every market. In parts of Latin America drugs are purely paid by the consumers, which will narrow your potential audience pool and require a more focused marketing theme. Reimbursement in China is handled by the government—but fi rst you must clear the extensive obstacles for the authorization of sale of new biosimilars or supergenerics. Meanwhile, in the U.S. your commercialization efforts will succeed or fail depending on your interactions and relationships with payers at the federal, state, and local level—an “alphabet soup” of potential partners, all of whom you must be able to work with.
- • Improve uptake and reimbursement through collaborations with hospitals, healthplans, and pharmacies
- • Focus on the priorities and informational needs of pharmacies and PBMs to boost the likelihood of reimbursement
- • What does the Avastin decision mean for the biologics and biosimilars approval mechanism and reimbursement?
|
Share this article with your social network, just click below to share now!
|
|
|
